From the FDA Drug Label
Pharmacokinetics Ingestion of 10 mg of dextroamphetamine sulfate in oral solution form by healthy volunteers produced an average peak dextroamphetamine blood level of 33.2 ng/mL. The Cmax of dextroamphetamine for a 10 mg oral dose is 33.2 ng/mL.
- However, the provided information does not specify the Cmax for a 70 mg oral dose of Vyvanse.
- Therefore, the Cmax for Vyvanse 70 mg oral cannot be determined from the given data 1.
From the Research
The Cmax of dextroamphetamine for Vyvanse 70 mg oral is approximately 80.3 ng/mL, as reported in the study by 2. This value is based on the mean maximum plasma drug concentration of d-amphetamine, which is the active component of Vyvanse. The study found that the median time to reach maximum plasma concentration (tmax) for d-amphetamine was 3.00 hours, indicating that the peak concentration typically occurs about 3 hours after ingestion. Vyvanse is a prodrug that requires enzymatic conversion in the bloodstream to release the active dextroamphetamine component, which contributes to its smoother effect profile and longer duration of action compared to immediate-release stimulants. Some key points to consider include:
- The pharmacokinetics of lisdexamfetamine, the prodrug component of Vyvanse, suggest a reduced potential for abuse, as reported in the study by 3.
- The efficacy of lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder (ADHD) has been established in several clinical trials, including those reported in the studies by 4, 5, and 6.
- Individual factors such as body weight, metabolism, liver function, and concurrent medications can influence the actual Cmax achieved in a specific person, highlighting the importance of personalized treatment approaches. Overall, the available evidence suggests that Vyvanse is a effective and well-tolerated treatment option for ADHD, with a pharmacokinetic profile that supports its use in clinical practice, as reported in the studies by 2, 4, 5, 6, and 3.